Research Analysts Set Expectations for RIGL FY2025 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Research analysts at HC Wainwright upped their FY2025 EPS estimates for shares of Rigel Pharmaceuticals in a report released on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $6.68 for the year, up from their prior forecast of $6.49. HC Wainwright currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2025 earnings at $1.34 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.53. The firm had revenue of $69.46 million during the quarter, compared to analysts’ expectations of $61.88 million. Rigel Pharmaceuticals had a net margin of 40.17% and a return on equity of 204.70%.

A number of other research analysts also recently issued reports on RIGL. Citigroup restated a “buy” rating on shares of Rigel Pharmaceuticals in a research note on Wednesday. Jefferies Financial Group raised Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the company from $23.00 to $42.00 in a report on Wednesday, November 5th. Zacks Research raised shares of Rigel Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Wall Street Zen upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Rigel Pharmaceuticals Stock Down 3.4%

RIGL opened at $37.78 on Wednesday. Rigel Pharmaceuticals has a one year low of $15.50 and a one year high of $52.24. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.14 and a current ratio of 2.28. The stock has a market capitalization of $685.71 million, a P/E ratio of 6.12 and a beta of 1.11. The business’s 50-day simple moving average is $43.26 and its 200-day simple moving average is $34.41.

Institutional Trading of Rigel Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RIGL. AlphaQuest LLC increased its stake in shares of Rigel Pharmaceuticals by 234.8% during the third quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 775 shares during the period. IFP Advisors Inc purchased a new stake in Rigel Pharmaceuticals in the 3rd quarter valued at approximately $55,000. Caitong International Asset Management Co. Ltd acquired a new position in Rigel Pharmaceuticals during the 3rd quarter worth approximately $62,000. RMG Wealth Management LLC purchased a new position in shares of Rigel Pharmaceuticals during the 2nd quarter worth approximately $41,000. Finally, Wexford Capital LP purchased a new position in shares of Rigel Pharmaceuticals during the 3rd quarter worth approximately $66,000. Hedge funds and other institutional investors own 66.23% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).